EQT Healthcare Growth to Accelerate Europa Biosite’s Expansion in Europe and North America

EQT Healthcare Growth to Accelerate Europa Biosite’s Expansion in Europe and North America

(IN BRIEF) EQT Healthcare Growth will acquire a controlling interest in Europa Biosite from Adelis Equity. Europa Biosite, based in Stockholm, distributes over ten million life science research products—antibodies, biochemicals, diagnostic kits, and biospecimens—to more than 60,000 researchers across 17 European and North American markets. Under EQT’s stewardship, the company will pursue commercial excellence initiatives, digital platform upgrades, broader product availability, and continued M&A, leveraging EQT’s extensive experience with companies such as Azelis and Beijer Ref. Kate Swann will chair the Board, and EQT advisors will guide Europa Biosite’s strategy to capitalize on growing demand for advanced research tools.

(PRESS RELEASE) STOCKHOLM, 4-Jul-2025 — /EuropaWire/ — EQT Healthcare Growth (“EQT”) has reached an agreement to acquire a majority stake in Europa Biosite—a leading distributor of research-use-only life science reagents, chemicals, and biological materials—from Adelis Equity. Headquartered in Stockholm, Europa Biosite operates in 17 countries across Europe and North America, serving over 60,000 academic and biopharma researchers.

The company’s extensive catalog includes more than ten million products—ranging from antibodies and biochemicals to diagnostic kits and ethically sourced biospecimens—sourced from a broad network of specialized suppliers. Europa Biosite has established itself as a trusted partner by combining deep local market knowledge with strong technical sales support, meeting the needs of a fragmented but well-funded life sciences research sector.

Under EQT’s ownership, Europa Biosite will embark on its next growth phase through a series of commercial excellence programs, digital platform enhancements, expanded product accessibility, and targeted M&A activity. Drawing on EQT’s 30-year track record in scaling healthcare and distribution companies—including partnerships with Azelis, Beijer Ref, and OEM International—Europa Biosite will accelerate its own-brand biospecimen offering, strengthen its geographical footprint, and modernize its digital infrastructure. Kate Swann, a Senior Industrial Advisor at EQT and former Chairperson of Beijer Ref, will chair Europa Biosite’s Board.

Rikke Kjær Nielsen, Partner on the EQT Healthcare Growth team, said: “Europa Biosite plays a crucial role in enabling scientific breakthroughs by connecting thousands of laboratories with essential reagents. With EQT’s support, the company will enhance its digital tools, deepen supplier relationships, and accelerate its M&A strategy to meet rising demand for advanced research tools.”

Sune Schmølker, CEO of Europa Biosite, added: “Partnering with EQT marks a pivotal moment for us. Their expertise in scaling specialized distributors will allow us to reach new customers, elevate our service standards, and introduce innovative products that drive research forward.”

Kate Swann remarked: “I’m honored to chair Europa Biosite’s Board and leverage my experience in specialized distribution to support the company’s ambitious growth plans. The life sciences sector demands agility and innovation, and Europa Biosite is well-positioned to deliver both.”

About EQT
EQT is a purpose-driven global investment organization with EUR 273 billion in total assets under management (EUR 142 billion in fee-generating assets under management) as of 31 March 2025, within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram

About Europa Biosite
Europa Biosite is a specialist distributor of research reagents, carrying a portfolio of over 10 million SKUs to support thousands of researchers across Europe and North America in reaching their research objectives. The company has 180 employees covering 17 countries; the majority of these are scientifically trained and therefore able to provide expert technical support to customers. Over the past 7 years, the company has completed 7 acquisitions, strengthening its commercial footprint and adding innovative products to the portfolio.

More info: www.europabiosite.com

Media Contact:

email: press@eqtpartners.com

SOURCE: EQT